Actively Recruiting

Phase 2
Age: 0Years - 21Years
All Genders
NCT04356469

TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

Led by Johns Hopkins All Children's Hospital · Updated on 2025-06-24

17

Participants Needed

1

Research Sites

309 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research is being done to learn if a new type of haploidentical transplantation using TCR alpha beta and CD19 depleted stem cell graft from the donor is safe and effective to treat the patient's underlying condition. This study will use stem cells obtained via peripheral blood or bone marrow from parent or other half-matched family member donor. These will be processed through a special device called CliniMACS, which is considered investigational.

CONDITIONS

Official Title

TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

Who Can Participate

Age: 0Years - 21Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of severe sickle cell disease with specific complications such as stroke, neuropsychological impairment, frequent pain episodes, or recurrent acute chest syndrome
  • Diagnosis of thalassemia major with transfusion dependency or genetic confirmation
  • Diagnosis of bone marrow failure syndromes or autoimmune cytopenias refractory to conventional treatments
  • Suitable genotypic match with donor at specific HLA genetic loci
  • Adequate organ function including heart, lung, kidney, and liver as defined by clinical criteria
  • Karnofsky or Lansky performance score of 50 or higher
  • Signed written informed consent
Not Eligible

You will not qualify if you...

  • Presence of an HLA-matched sibling donor able and willing to donate bone marrow
  • Pregnant or breastfeeding females
  • HIV infection or uncontrolled fungal, bacterial, or viral infections
  • Prior solid organ transplant
  • Active graft versus host disease (GVHD) grade greater than II or chronic extensive GVHD from previous transplant
  • Liver disease including cirrhosis, extensive fibrosis, or active hepatitis in patients with chronic transfusion history and elevated ferritin levels

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Johns Hopkins All Children's Hospital

St. Petersburg, Florida, United States, 33701

Actively Recruiting

Loading map...

Research Team

J

Jade Hanson, MSN

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here